跳转到内容

LLM: Fujitsu tackles drug loss in Japan to accelerate digitalization of clinical trials

Fujitsu today announced that it will begin initiatives to attract global clinical trials to Japan and tackle the ‚drug loss‘ issue by working with pharmaceutical companies and medical institutions to build a new medical data ecosystem. The efforts come under the Fujitsu Uvance Healthy Living, which aims to improve people’s well-being.

In July 2024, Fujitsu formed a strategic partnership with Paradigm Health, Inc., a US startup that provides one of the world’s most advanced clinical trial platforms. Through utilizing this platform, Fujitsu’s Healthy Living Platform, and the Fujitsu Kozuchi AI service, Fujitsu and Paradigm will facilitate the collection and processing of data stored at medical institutions and speed up the clinical trial planning process.

In addition, starting today, Fujitsu will release Patient-centric Clinical Trials, a new service for automatically creating clinical trial documents using Fujitsu’s proprietary large language model (LLM). This service will be positioned in the company’s Healthy Living portfolio.

作者头像
LabNews Media LLC
labnews.ai 的主编是 Marita Vollborn 和 Vlad Georgescu。自 1994 年以来,他们一直是畅销书作家、科学作家和科学记者。更多关于他们的写作信息,请访问 X-Press Journalistenbüro (https://xpress-journalisten.com)。更多维基百科信息:关于 Marita:https://de.wikipedia.org/wiki/Marita_Vollborn 关于 Vlad:https://de.wikipedia.org/wiki/Vlad_Georgescu
LabNews Media LLC

LabNews Media LLC

labnews.ai 的主编是 Marita Vollborn 和 Vlad Georgescu。自 1994 年以来,他们一直是畅销书作家、科学作家和科学记者。更多关于他们的写作信息,请访问 X-Press Journalistenbüro (https://xpress-journalisten.com)。更多维基百科信息:关于 Marita:https://de.wikipedia.org/wiki/Marita_Vollborn 关于 Vlad:https://de.wikipedia.org/wiki/Vlad_Georgescu